On May 22, 2025, Ascentage Pharma Group International announced the clinical data of Lisaftoclax showing therapeutic potential for Venetoclax-refractory patients, with further results presented at the ASCO 2025 Annual Meeting on May 23, 2025.
AI Assistant
ASCENTAGE PHARMA GROUP INTERNATIONAL
2025
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.